WO2006053521A1 - Einweginhalator - Google Patents
Einweginhalator Download PDFInfo
- Publication number
- WO2006053521A1 WO2006053521A1 PCT/DE2005/002004 DE2005002004W WO2006053521A1 WO 2006053521 A1 WO2006053521 A1 WO 2006053521A1 DE 2005002004 W DE2005002004 W DE 2005002004W WO 2006053521 A1 WO2006053521 A1 WO 2006053521A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- combustion
- disposable inhaler
- inhaler according
- magnesium
- substances
- Prior art date
Links
- 238000002485 combustion reaction Methods 0.000 claims abstract description 112
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 40
- 229910052751 metal Inorganic materials 0.000 claims abstract description 38
- 239000002184 metal Substances 0.000 claims abstract description 38
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000011777 magnesium Substances 0.000 claims abstract description 29
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 29
- 239000004480 active ingredient Substances 0.000 claims abstract description 26
- 239000000126 substance Substances 0.000 claims abstract description 23
- 229910052742 iron Inorganic materials 0.000 claims abstract description 16
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 9
- 239000011575 calcium Substances 0.000 claims abstract description 9
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 9
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229910045601 alloy Inorganic materials 0.000 claims abstract description 8
- 239000000956 alloy Substances 0.000 claims abstract description 8
- 239000011591 potassium Substances 0.000 claims abstract description 8
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 8
- 239000011734 sodium Substances 0.000 claims abstract description 8
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 8
- 239000011701 zinc Substances 0.000 claims abstract description 8
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims abstract 3
- 229910052799 carbon Inorganic materials 0.000 claims abstract 3
- 239000011574 phosphorus Substances 0.000 claims abstract 3
- 229910052698 phosphorus Inorganic materials 0.000 claims abstract 3
- 239000013543 active substance Substances 0.000 claims description 21
- 210000002268 wool Anatomy 0.000 claims description 12
- 239000003937 drug carrier Substances 0.000 claims description 11
- 239000011888 foil Substances 0.000 claims description 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 10
- 239000001301 oxygen Substances 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000001569 carbon dioxide Substances 0.000 claims description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 5
- 239000011230 binding agent Substances 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 229910000640 Fe alloy Inorganic materials 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 229910000861 Mg alloy Inorganic materials 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 206010053615 Thermal burn Diseases 0.000 claims 4
- 229910001297 Zn alloy Inorganic materials 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000013011 mating Effects 0.000 claims 1
- 150000002739 metals Chemical class 0.000 abstract description 16
- 235000019504 cigarettes Nutrition 0.000 abstract description 15
- 230000000711 cancerogenic effect Effects 0.000 abstract description 12
- 241000208125 Nicotiana Species 0.000 abstract description 11
- 235000002637 Nicotiana tabacum Nutrition 0.000 abstract description 11
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract description 10
- 231100000315 carcinogenic Toxicity 0.000 abstract description 10
- 229960002715 nicotine Drugs 0.000 abstract description 10
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract description 10
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 abstract description 6
- 229910002091 carbon monoxide Inorganic materials 0.000 abstract description 6
- 239000000021 stimulant Substances 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 239000002956 ash Substances 0.000 description 9
- 239000000919 ceramic Substances 0.000 description 9
- 239000000395 magnesium oxide Substances 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 230000008020 evaporation Effects 0.000 description 6
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 6
- 239000001095 magnesium carbonate Substances 0.000 description 6
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 6
- 239000004576 sand Substances 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 239000000428 dust Substances 0.000 description 5
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000779 smoke Substances 0.000 description 5
- 238000000137 annealing Methods 0.000 description 4
- 229910044991 metal oxide Inorganic materials 0.000 description 4
- 150000004706 metal oxides Chemical class 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- QWDJLDTYWNBUKE-UHFFFAOYSA-L magnesium bicarbonate Chemical compound [Mg+2].OC([O-])=O.OC([O-])=O QWDJLDTYWNBUKE-UHFFFAOYSA-L 0.000 description 3
- 239000002370 magnesium bicarbonate Substances 0.000 description 3
- 229910000022 magnesium bicarbonate Inorganic materials 0.000 description 3
- 235000014824 magnesium bicarbonate Nutrition 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000000197 pyrolysis Methods 0.000 description 3
- 229910052624 sepiolite Inorganic materials 0.000 description 3
- 235000019355 sepiolite Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 235000002918 Fraxinus excelsior Nutrition 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000004113 Sepiolite Substances 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003344 environmental pollutant Substances 0.000 description 2
- MSNWSDPPULHLDL-UHFFFAOYSA-K ferric hydroxide Chemical compound [OH-].[OH-].[OH-].[Fe+3] MSNWSDPPULHLDL-UHFFFAOYSA-K 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 239000011147 inorganic material Substances 0.000 description 2
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- 229910052919 magnesium silicate Inorganic materials 0.000 description 2
- 235000019792 magnesium silicate Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000019645 odor Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 231100000719 pollutant Toxicity 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 238000004804 winding Methods 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 238000005275 alloying Methods 0.000 description 1
- 238000007743 anodising Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004049 embossing Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910001092 metal group alloy Inorganic materials 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 150000004005 nitrosamines Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007788 roughening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24D—CIGARS; CIGARETTES; TOBACCO SMOKE FILTERS; MOUTHPIECES FOR CIGARS OR CIGARETTES; MANUFACTURE OF TOBACCO SMOKE FILTERS OR MOUTHPIECES
- A24D1/00—Cigars; Cigarettes
- A24D1/22—Cigarettes with integrated combustible heat sources, e.g. with carbonaceous heat sources
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention relates to a disposable inhaler for inhaling active ingredients, wherein the active ingredients are stored in a drug carrier and by heat from this solvable.
- Inhalation is the uptake of active ingredients in the human body through the lungs.
- This type of active substance intake serves for a medical purpose, on the other hand, the stimulant application and in particular the consumption of the tobacco smoke.
- the method of consuming tobacco smoke has remained unchanged for a long time. So the tobacco is burned slowly in a pipe, a cigar or a cigarette. In this combustion, the nicotine contained in the tobacco evaporates - the stimulant. Furthermore, during combustion, odors and flavorings as well as combustion residues are formed, which are inhaled together with the stimulant nicotine as tobacco smoke.
- This type of stimulant use is harmful to the human body, since it not only the stimulant nicotine and possibly odor and/orsstof ⁇ fe, but also harmful combustion residues are supplied via the lungs.
- nicotine is one of the least harmful components of Tabakrau ⁇ ches.
- this active ingredient causes a contraction in particular of peripheral blood vessels and can thereby lead to a reduction of the blood circulation and thus the Sauerstoff ⁇ supply of body areas.
- this disadvantage of the stimulant nicotine is reversible, because it is completely abolished when the absorbed nicotine is eliminated from the body.
- no damage takes place.
- Far more serious are the kan ⁇ zerogene incineration residues of various classes of substances incorporated in the inhalation of tobacco smoke, such.
- an inhalable vapor or aerosol must be prepared using, for example, an electrically powered nebulizer device.
- an electrically powered nebulizer device Such devices are elaborately designed and suitable only for the application of water-soluble substances. They have to be supplied with electrical energy. This alone requires a stationary device use, for example, in the hospital or in the apartment.
- a spray device As a mobile variant of the application of water-soluble substances, a spray device is known.
- an electrically heated evaporator is known.
- Such devices are only suitable for stationary use, since electrical power must be supplied for the evaporation.
- the heating of the air by the combustion of metals has the advantage that no carbonaceous substrates of natural or artificial origin are burned.
- neither carbon monoxide nor carcinogenic organic substances can form.
- the product of combustion of metals or metal alloys are solid metal oxides which accumulate as ash. A small part of it is entrained as fine dust by the air flow and reaches the respiratory organs unfiltered. Part of this metal oxide dust is bound by the mucus mucus and excreted, and the remainder is resorbed in the lungs. Since the amount consumed is very small, even with heavy consumption (the concentration of dust in the inhaled air is below the MAK value), there is no damage to the lungs or other organs.
- a filter is additionally used to reduce it even further.
- This filter can be a normal cigarette filter. Since the disposable inhaler according to the invention is a special combustion residue, special filters designed for these residues can also be used here.
- the filter In a disposable inhaler having a magnesium foil shell and a magnesium wool sand mixture combustion body ( Figure 2), the filter could be sepiolite, a magnesium silicate. In Table 1, substances are collected which arise in the combustion of a cigarette from tobacco.
- the disposable inhaler according to the invention is constructed similar to a cigarette. It basically consists of a rod-shaped, air-permeable combustion body. This is, apart from the end faces, surrounded by a coating or provided with a coating.
- the combustion body consists of magnesium, pyrophoric iron, the alloys mentioned below or contains these metals as combustible components.
- the combustion body is simultaneously the drug carrier, in another the drug carrier and the combustion body are separate entities. If appropriate, additional components are added to the combustion body in addition to the combustion metal as combustion regulation, eg. As magnesium oxide or ceramic particles.
- the active substances which are either incorporated in or on the combustion body or are contained in the separate active substance carrier, are vaporized by the air heated by the metal combustion and supplied to the lungs.
- the casing with the active substance carrier may have a filter for retaining metal oxide dust which is obtained during the combustion process.
- the drug carrier When used as a stimulant composition of the invention contains as active ingredient pure nicotine and optionally a pleasing the smell and / or taste, but harmless to the smoker perfuming.
- the drug carrier When used as a disposable medical inhaler, contains a medicinal agent which, like nicotine, is vaporized during smoking and inhaled into the lung in vapor form.
- the combustion body of metal foil, metal wire, metal wool or an inorganic, air-permeable structure is formed containing combustible metallic constituents.
- the "physiological" metals magnesium and iron are considered as metals for the construction of the combustion body.
- the metals sodium, potassium and calcium which also occur in the body, react rapidly with water to give hydrogen in the pure state
- oxides also form on their combustion which combine with water to form strongly basic, corrosive hydroxides, they can only be used as constituents of alloys in small proportions, eg less than two percent, another "physiological" metal used as an alloying constituent can be used is zinc.
- Magnesium can be ignited with a lighter if it is present as a thin wire, foil or in small grains or particles with a size of less than one millimeter in diameter and burns with glistening light until the end, even if the source of ignition is removed.
- the ignition temperature is 600 degrees Celsius. This is also the case with magnesium alloys with small proportions of sodium, potassium or calcium, such as, for. Example, with an alloy of 99.97 percent magnesium and 0.03 percent calcium.
- Iron if present in a compact piece with a smooth surface, is very difficult to ignite. However, when iron particles with a microporous surface are used, the situation changes. The surface can develop such a great reactivity that, for example, iron sponges or iron powder ignite spontaneously in the air (pyrophoric iron).
- the temperature at which the iron exhibits pyrophoric behavior is widely adjustable by the manufacturing process and by alloys with other metals.
- pyrophoric iron can be produced for the application according to the invention, which has an ignition temperature of 250 degrees Celsius and can be ignited with a match or lighter.
- the disposable inhaler is suitable for an inhalation period of one to five minutes.
- the combustion body must continue to burn if no air is drawn in through the disposable inhaler.
- the ratio between the surface area and the volume of the combustion body, the heat release to the environment and the amount of oxygen fed in are decisive for the speed of combustion, for the further burning or extinguishing.
- the porous, rod-shaped combustion body is, apart from the end faces, basically surrounded by a tubular sheathing or coating.
- inert to heating inorganic materials (ceramic) or inorganic materials are used, which emit only water, carbon dioxide and / or oxygen when heated. If the shell is a combustible metal foil, it burns to ashes together with the combustion body as shown in FIGS. 2, 3, 5, 6 and 8 presented and described in the respective drawing descriptions. Is the shell made of a material that loses its strength by the action of heat, such.
- B. the shell of bound by magnesium carbonate magnesia powder in Fig. 1, it is also destroyed during inhalation and forms a powdery residue.
- a tube of ceramic or a shell of aluminum foil is used, which does not burn with. In this case, the combustion zone travels through the tube.
- the accumulated residue (ash) can be periodically removed from the tube during inhalation.
- An essential prerequisite for the desired effect of the disposable inhaler according to the invention is the prevention of pyrolysis (thermal decomposition) of the inputs or accumulated active ingredients, since otherwise the undesirable pollutants - toxic carbon monoxide and / or carcinogenic substances - arise.
- the active substance is contained in the combustion body, as in FIGS. 1, 2, 3, 4, 5 and 7, it has proven to be advantageous to keep the area of inflammation of the combustion body free of active substance. As shown in FIG. 9, the combustion zone with its high temperatures is always located in a region of the combustion body which is free of active ingredient.
- the active ingredient is on the inner wall of separate tubes which pass through the combustion body.
- the tubes are heated and the partial air flow passing through the tubes entrains the vaporized active ingredient.
- the thermal resistance of the drug delivery tubes ensures that the interior of the tube reaches the necessary evaporation values from 150 degrees Celsius to 350 degrees Celsius, but is much colder than the incandescent combustion zone, at temperatures between 600 degrees Celsius (fill components) and 2400 degrees Celsius (burning metal particles) prevail. Damage to the active substance by pyrolysis is thus excluded.
- the active ingredient is in a separate drug carrier, which is simultane- ously the filter. He is located behind the combustion body. The air heated in the combustion body, when it reaches the filter, has already given off some of the heat and has cooled down somewhat.
- FIGS. 1 to 8 it shows:
- Figure 1 shows the disposable inhaler in cigarette-like form with magnesium grains as a combustible component of the combustion body.
- FIG. 3 shows the disposable inhaler of a pyrophoric iron foil combustion body
- FIG. 4 shows the disposable inhaler with a combustion body of a sponge-like structure
- FIG. 5 shows the disposable inhaler with combustion body of metal coils and ceramic grains
- FIG. 6 shows the disposable inhaler with active substance in special drug carrier tubes
- Fig. 7 shows the disposable inhaler with a non-combustible or decomposable shell
- 8 shows the disposable inhaler with a separation of combustion body and active substance carrier.
- FIG. 9 shows the mode of operation of pyrolysis prevention in disposable inhalers according to FIGS. 1 to 5 and FIG. 7.
- the combustion body 3 consists of hard burned grains of magnesium oxide 8, grains of magnesium metal 7 and magnesium carbonate as binder. Both types of grains have a size of approx. 0.8 mm. A mixture of 60 percent magnesium oxide granules and 40 percent magnesium granules is used in this example. The grains are connected only at their contact points by magnesium carbonate, so that empty Zwi ⁇ spaces remain, can flow through the air. This type of binding arises from the fact that a bed in the form of the combustion body 3 is impregnated with magnesium hydrogen carbonate solution and then dried.
- the combustion body 3 has a drug-loaded part B and an active part free front part A. Both parts are made separately. One part is tapered at one end, so that it fits into a cylindrical recess in the end face of the other. In addition to this fit, the two parts are interconnected by the shell 1.
- the drug-loaded part B is produced by impregnating a combustion body 3 with an organic solvent in which the active ingredient is dissolved, and then allowing the solvent to evaporate.
- the shell 1 is produced by applying a paste of fine magnesia powder and magnesium bicarbonate solution to the cylinder jacket of the two combined parts of the combustion body 3.
- a conventional cigarette filter is used in this example.
- the disposable inhaler is set on fire for inhalation at the front end and then smoked like a cigarette.
- the combustion heat causes the binder to release magnesium carbonate destroyed by carbon dioxide, whereby the combustion body 3 loses its strength and the spent parts can be repelled as ash.
- the combustion body 3 consists of a mixture of magnesium wool and sand (silicon dioxide). It is divided into a drug-free section A and a drug-containing section B, which are prepared separately.
- the active substance in Section B sticks to the surface of the grains of sand or the metal fibers.
- the filter 2 consists in this example of the porous sepiolite, a magnesium silicate mineral, which is also known under the name Meerschaum. Both sections of the combustion body 3 and the filter 2 are held together by the enveloping film.
- the disposable inhaler is set on fire for inhalation at the front end and then smoked like a cigarette.
- the fibers of the magnesium wool, which form the combustion body 3 with the grains of sand, and the coating film burn ver ⁇ to magnesium oxide, which is stripped off together with the sand grains as ash.
- the combustion body 3 shows a variant of the disposable inhaler which consists of the combustion body 3, the filter 2 and the shell 1 in longitudinal section L and cross section Q.
- the combustion body 3 consists of a wound iron foil 9 provided with a dimple embossing.
- the combustion body 3 is at the same time the drug carrier, but the front part of the combustion body 3 is drug-free.
- the shell 1 is formed by the last winding layer of the film.
- Q shows the wound film of the combustion body 3 in cross section.
- the unwound film 9 with the knobs is shown in the plan view D and in the profile view P. It is 0.03 mm thick and coated with pyrophoric iron powder in a thickness of 0.5 mm. In Section B, the coating carries the active ingredient, while Section A remains active.
- the coating is created by first applying a 0.3 mm thick layer of pyrophoric iron powder to the film and annealing at 900 degrees Celsius in an argon atmosphere.
- the iron dust grains sinter together with each other and with the film 9. They also lose their pyrophoric properties through annealing. To restore it, moisten the layer in the presence of oxygen and let it rust.
- the resulting iron (III) hydroxide is then converted back into pyrophoric iron by reduction in a hydrogen atmosphere at 600 degrees Celsius.
- the Ignition temperature of the layer is then adjusted to 250 degrees Celsius by brief annealing in the Ar ⁇ gonatmospreheat.
- the active ingredient is applied to this coating in Section B by spraying a solution of the active agent and allowing the solvent to evaporate.
- the active ingredient-free edge strip on the film later forms the drug-free front part of the combustion body 3.
- the film 9 is finally wound into a tube.
- the nubs create gaps between the winding layers, which serve for Heiltremng.
- the disposable inhaler is set on fire for inhalation at the front end and then smoked like a cigarette.
- the combustion body 3 is formed by an open-pored metal sponge made of pyrophoric iron or a pyrophoric iron alloy.
- coarse magnesium grains of 2 to 3 mm in diameter with fine magnesium and iron dust are compressed at 500 degrees Celsius under a pressure of 20 MPa to form a stick in cigarette size.
- the metal grains sinter together.
- the magnesium is dissolved out by sodium or potassium hydroxide from the structure, so that there is an open-pore sponge iron in the form of the desired combustion body 3.
- the combustion body 3 consists of the active substance-laden rear part B and the active substance-free front part A, which are produced separately.
- the active ingredient is introduced into the pores of section B via a suitable solvent. Both parts are held together with the filter 2 by the shell 1, which is formed by a very thin iron foil of 0.03 mm thickness.
- the disposable inhaler is set on fire for inhalation at the front end and then smoked like a cigarette.
- Fig. 5 shows a disposable inhaler
- the combustion body 3 consists of several, 0.3mm thick, coiled magnesium wires 10 and porous ceramic particles 8 of about lmm diameter.
- the magnesium wires 10 carry an oxide layer reinforced by anodizing so that they do not burn too quickly.
- the combustion body 3 is held together with the filter 2 by the shell 1, which is formed by a 0.05 mm thick Magne ⁇ siumfolie together.
- the active substance is in the pores and on the surface of the ceramic particles 8 of the section B.
- the section A is drug-free.
- the magnesium wires 10 burn off slowly after ignition from the area of inflammation and continue to release the active ingredient in the manner described.
- the shell 1 and the magnesium wires 10 of the combustion body 3 were ⁇ destroys the burning and are stripped off together with the ceramic Wirkstoff ⁇ carrier 8 (which then no longer contain active ingredient) as ash.
- the shell 1 is formed by a 0.05 mm thick magnesium foil and holds the filter 2 and the combustion body 3 together.
- the combustion body 3 is made of metal wool into which the drug carrier tubes 6 are embedded from magnesia powder bound with magnesium carbonate. During inhalation, part of the air flows through the metal wool of the combustion body 3 and part through the lumens of the drug carrier tubes 6 on the inner walls of which the drug is in the form of a film.
- the active substance carrier tubes 6 are heated by the burning combustion body 3, the active substance evaporates on the inside and is entrained by the air flow through the active ingredient carrier tube 6.
- the disposable inhaler is ignited like a cigarette, then the metal wool and sheath 1 burn slowly. The binder of the active ingredient carrier tube 6 is thereby destroyed with the release of carbon dioxide, so that the remaining magnesium oxide can be stripped off together with the ashes of the combustion body 3 and the coating residues.
- FIG. 7 shows a disposable inhaler in which the casing 1 consists of a thin-walled ceramic tube or aluminum foil.
- the shell 1 In the shell 1 are a conventional cigarette filter and a combustion body 3 made of metal wool.
- the combustion body 3 consists of two parts, an active substance-free in the area A and one, which carries the active substance as a film on the fibers of the metal wool, in the area B.
- the combustion body 3 is ignited at the front open end of the shell 1.
- a combustion zone forms, which slowly travels through the interior of the shell 1.
- the resulting ash can be removed during the smoking process through the front opening by dumping.
- the shell 1 remains in this embodiment after completion of the combustion process as waste.
- FIG. 8 shows a disposable inhaler in which the entire combustion body 3 is free of active ingredient. It consists of a mixture of magnesium wool and sand. The active substance is incorporated in the pores of the filter 2.
- the shell 1 is formed from a 0.05 mm thick magnesium foil.
- the end of the combustion body 3 is set on fire. He burns slowly while inhaling. The air sucked through it heats up. At the beginning of the combustion process, the air that reaches the filter 2, not yet reached the evaporation temperature, so that initially only a small mobilization of the drug by evaporation or sublimation occurs. The further the combustion progresses, the higher the temperature of the air reaching the filter 2 and thus the entrained amount of active ingredient, until its complete evaporation.
- FIG. 9 shows that the air sucked in during inhalation first flows through an optionally existing ash residue 12 into the combustion zone 11 of the combustion body.
- the combustion takes place at the beginning of the inhalation (of the roughening) in the front, drug-free part of the disposable inhaler.
- the air After the air has been heated in the combustion zone, it reaches behind the combustion zone the here not yet at evaporation temperature, drug-loaded part of the combustion body 4, evaporates the active ingredient here and leads the drug vapor in the direction of arrow to the non-burning end of the disposable inhaler.
- the slowly migrating combustion zone continuously reaches the regions of the combustion body 5 which no longer contain an active substance.
- Carcinogenic substances are characterized by their classification by the IARC (International Association for Research on Cancer) in parenthesis after the substance name. For substances that are not yet classified by the IARC, the classification is stated by the DFG (German Research Community).
- the abbreviations have the following meanings:
- IDFG "Substances that cause cancer in humans”
- 2DFG Substances that are carcinogenic to humans
- 3DFG Substances that give rise to concern because of proven or possible carcinogenic effects.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Manufacture Of Tobacco Products (AREA)
- Cigarettes, Filters, And Manufacturing Of Filters (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007541663A JP2008520292A (ja) | 2004-11-22 | 2005-11-09 | 使い捨て吸入器 |
US11/719,875 US20090162294A1 (en) | 2004-11-22 | 2005-11-09 | Disposable inhaler |
GB0709512A GB2434955A (en) | 2004-11-22 | 2007-05-17 | Disposable inhaler |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004056309 | 2004-11-22 | ||
DE102004056309.8 | 2004-11-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006053521A1 true WO2006053521A1 (de) | 2006-05-26 |
WO2006053521B1 WO2006053521B1 (de) | 2006-11-02 |
Family
ID=36097056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DE2005/002004 WO2006053521A1 (de) | 2004-11-22 | 2005-11-09 | Einweginhalator |
Country Status (5)
Country | Link |
---|---|
US (1) | US20090162294A1 (de) |
JP (1) | JP2008520292A (de) |
CN (1) | CN101076263A (de) |
GB (1) | GB2434955A (de) |
WO (1) | WO2006053521A1 (de) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2138057A1 (de) | 2008-06-27 | 2009-12-30 | Olig AG | Rauchfreie Zigarette |
EP2191735A1 (de) * | 2008-11-28 | 2010-06-02 | Olig AG | Rauchfreie Zigarette |
WO2014101092A1 (zh) * | 2012-12-28 | 2014-07-03 | Wu Changming | 烟草蒸发器 |
CN103929984A (zh) * | 2011-12-29 | 2014-07-16 | 菲利普莫里斯生产公司 | 用于吸烟制品的复合热源 |
CN108872145A (zh) * | 2018-04-26 | 2018-11-23 | 中国烟草总公司郑州烟草研究院 | 一种炭加热卷烟供热体材料逐口燃烧放热量的测量方法 |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2113178A1 (de) | 2008-04-30 | 2009-11-04 | Philip Morris Products S.A. | Elektrisch beheiztes Rauchsystem mit einem Element zur Flüssigkeitsspeicherung |
EP2319334A1 (de) * | 2009-10-27 | 2011-05-11 | Philip Morris Products S.A. | Rauchsystem mit einem Flüssigkeitsspeicherteil |
BR112013030413A2 (pt) | 2011-05-31 | 2017-03-21 | Philip Morris Products Sa | hastes para uso em artigos de fumo |
WO2013034459A1 (en) | 2011-09-06 | 2013-03-14 | British American Tobacco (Investments) Limited | Heating smokeable material |
US9854839B2 (en) | 2012-01-31 | 2018-01-02 | Altria Client Services Llc | Electronic vaping device and method |
EP2816913B1 (de) | 2012-02-22 | 2019-01-09 | Altria Client Services LLC | Elektronische rauchartikel und verbessertes heizelement |
EP2817051B1 (de) | 2012-02-22 | 2017-07-26 | Altria Client Services LLC | Elektronischer rauchartikel |
US8807140B1 (en) | 2012-08-24 | 2014-08-19 | Njoy, Inc. | Electronic cigarette configured to simulate the texture of the tobacco rod and cigarette paper of a traditional cigarette |
GB201217067D0 (en) | 2012-09-25 | 2012-11-07 | British American Tobacco Co | Heating smokable material |
WO2014061477A1 (ja) * | 2012-10-18 | 2014-04-24 | 日本たばこ産業株式会社 | 非燃焼型香味吸引器 |
USD691765S1 (en) | 2013-01-14 | 2013-10-15 | Altria Client Services Inc. | Electronic smoking article |
USD691766S1 (en) | 2013-01-14 | 2013-10-15 | Altria Client Services Inc. | Mouthpiece of a smoking article |
USD695449S1 (en) | 2013-01-14 | 2013-12-10 | Altria Client Services Inc. | Electronic smoking article |
USD849993S1 (en) | 2013-01-14 | 2019-05-28 | Altria Client Services | Electronic smoking article |
USD841231S1 (en) | 2013-01-14 | 2019-02-19 | Altria Client Services, Llc | Electronic vaping device mouthpiece |
GB201311620D0 (en) | 2013-06-28 | 2013-08-14 | British American Tobacco Co | Devices Comprising a Heat Source Material and Activation Chambers for the Same |
BR302014001648S1 (pt) | 2013-10-14 | 2015-06-09 | Altria Client Services Inc | Configuração aplicada em artigo de fumo |
GB201500582D0 (en) | 2015-01-14 | 2015-02-25 | British American Tobacco Co | Apparatus for heating or cooling a material contained therein |
US20170055575A1 (en) | 2015-08-31 | 2017-03-02 | British American Tobacco (Investments) Limited | Material for use with apparatus for heating smokable material |
US11924930B2 (en) | 2015-08-31 | 2024-03-05 | Nicoventures Trading Limited | Article for use with apparatus for heating smokable material |
US20170055584A1 (en) | 2015-08-31 | 2017-03-02 | British American Tobacco (Investments) Limited | Article for use with apparatus for heating smokable material |
GB201517471D0 (en) * | 2015-10-02 | 2015-11-18 | British American Tobacco Co | Apparatus for generating an inhalable medium |
US20170119046A1 (en) | 2015-10-30 | 2017-05-04 | British American Tobacco (Investments) Limited | Apparatus for Heating Smokable Material |
US20170119047A1 (en) | 2015-10-30 | 2017-05-04 | British American Tobacco (Investments) Limited | Article for Use with Apparatus for Heating Smokable Material |
US10455863B2 (en) | 2016-03-03 | 2019-10-29 | Altria Client Services Llc | Cartridge for electronic vaping device |
US10433580B2 (en) | 2016-03-03 | 2019-10-08 | Altria Client Services Llc | Methods to add menthol, botanic materials, and/or non-botanic materials to a cartridge, and/or an electronic vaping device including the cartridge |
US10368580B2 (en) | 2016-03-08 | 2019-08-06 | Altria Client Services Llc | Combined cartridge for electronic vaping device |
US10368581B2 (en) | 2016-03-11 | 2019-08-06 | Altria Client Services Llc | Multiple dispersion generator e-vaping device |
US10357060B2 (en) | 2016-03-11 | 2019-07-23 | Altria Client Services Llc | E-vaping device cartridge holder |
CN110506986B (zh) * | 2018-05-21 | 2021-10-26 | 湖南中烟工业有限责任公司 | 一种烟草颗粒及其制备方法、低温发烟体及其制备方法 |
CN112244367B (zh) * | 2019-07-22 | 2022-07-19 | 湖北中烟工业有限责任公司 | 一种发热体及其制备方法和具有该发热体的抽烟设备 |
CN110942810A (zh) * | 2019-10-25 | 2020-03-31 | 东北大学 | 一种基于热理论的气体燃料可燃极限预测方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3258015A (en) * | 1964-02-04 | 1966-06-28 | Battelle Memorial Institute | Smoking device |
EP0372985A2 (de) * | 1988-12-08 | 1990-06-13 | Philip Morris Products Inc. | Hitzequelle für einen Rauchartikel |
EP0514151A2 (de) * | 1991-05-13 | 1992-11-19 | Philip Morris Products Inc. | Hitzequelle aus unterschiedlichen Materialien |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4188192A (en) * | 1976-04-08 | 1980-02-12 | Levenson Michael K | Fire igniting method and apparatus |
US5396911A (en) * | 1990-08-15 | 1995-03-14 | R. J. Reynolds Tobacco Company | Substrate material for smoking articles |
US5285798A (en) * | 1991-06-28 | 1994-02-15 | R. J. Reynolds Tobacco Company | Tobacco smoking article with electrochemical heat source |
PT781101E (pt) * | 1994-09-07 | 2001-01-31 | British American Tobacco Co | Artigos para fumar |
US7458374B2 (en) * | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
-
2005
- 2005-11-09 US US11/719,875 patent/US20090162294A1/en not_active Abandoned
- 2005-11-09 WO PCT/DE2005/002004 patent/WO2006053521A1/de not_active Application Discontinuation
- 2005-11-09 JP JP2007541663A patent/JP2008520292A/ja active Pending
- 2005-11-09 CN CNA2005800424154A patent/CN101076263A/zh active Pending
-
2007
- 2007-05-17 GB GB0709512A patent/GB2434955A/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3258015A (en) * | 1964-02-04 | 1966-06-28 | Battelle Memorial Institute | Smoking device |
EP0372985A2 (de) * | 1988-12-08 | 1990-06-13 | Philip Morris Products Inc. | Hitzequelle für einen Rauchartikel |
EP0514151A2 (de) * | 1991-05-13 | 1992-11-19 | Philip Morris Products Inc. | Hitzequelle aus unterschiedlichen Materialien |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2138057A1 (de) | 2008-06-27 | 2009-12-30 | Olig AG | Rauchfreie Zigarette |
WO2009155958A1 (de) * | 2008-06-27 | 2009-12-30 | Olig Ag | Rauchfreie zigarette |
EP2191735A1 (de) * | 2008-11-28 | 2010-06-02 | Olig AG | Rauchfreie Zigarette |
CN103929984A (zh) * | 2011-12-29 | 2014-07-16 | 菲利普莫里斯生产公司 | 用于吸烟制品的复合热源 |
US10440990B2 (en) | 2011-12-29 | 2019-10-15 | Philip Morris Products S.A. | Composite heat source for a smoking article |
WO2014101092A1 (zh) * | 2012-12-28 | 2014-07-03 | Wu Changming | 烟草蒸发器 |
CN108872145A (zh) * | 2018-04-26 | 2018-11-23 | 中国烟草总公司郑州烟草研究院 | 一种炭加热卷烟供热体材料逐口燃烧放热量的测量方法 |
CN108872145B (zh) * | 2018-04-26 | 2020-07-21 | 中国烟草总公司郑州烟草研究院 | 一种炭加热卷烟供热体材料逐口燃烧放热量的测量方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101076263A (zh) | 2007-11-21 |
GB2434955A (en) | 2007-08-08 |
GB0709512D0 (en) | 2007-06-27 |
JP2008520292A (ja) | 2008-06-19 |
WO2006053521B1 (de) | 2006-11-02 |
US20090162294A1 (en) | 2009-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006053521A1 (de) | Einweginhalator | |
DE102006041544A1 (de) | Einweginhalator | |
DE69025113T2 (de) | Tabakrauchartikel | |
RU2616554C2 (ru) | Курительное изделие, содержащее сгораемый источник тепла с задним барьерным покрытием | |
US7290549B2 (en) | Chemical heat source for use in smoking articles | |
JP6695909B2 (ja) | 多層可燃性熱源 | |
US5357984A (en) | Method of forming an electrochemical heat source | |
EP0520231A2 (de) | Tabakrauchartikel mit elektrochemischer Hitzequelle | |
DE19854007C2 (de) | System zur Bereitstellung eines inhalierbaren Aerosols | |
EP2138057B1 (de) | Rauchfreie Zigarette | |
EP1128742A1 (de) | System zur bereitstellung eines inhalierbaren aerosols | |
EP1128743A1 (de) | System zur bereitstellung eines inhalierbaren aerosols | |
DD264612A5 (de) | Rauchware mit verbessertem brennstoffelement | |
KR20170020342A (ko) | 가연성 열원과 홀더를 포함하는 흡연 물품 및 그 제조 방법 | |
DE19854008A1 (de) | System zur Bereitstellung eines inhalierbaren Aerosols | |
PL203192B1 (pl) | Wyrób do palenia | |
WO2006002445A2 (de) | Rauchlose zigarette | |
DE4001394C2 (de) | Rauchartikel | |
WO2023227789A1 (de) | Evaporator zum extrahieren und filtern von wirkstoffen aus biologischen materialien durch erhitzen | |
EP4510852A1 (de) | Evaporator zum extrahieren und filtern von wirkstoffen aus biologischen materialien durch erhitzen | |
EP4068998B1 (de) | Brennbare wärmequelle mit kohlenstoff und calciumperoxid | |
DE2723553A1 (de) | Schadstoffarme tabakwaren | |
DE2712800A1 (de) | Schadstoffarme tabakwaren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007541663 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1676/KOLNP/2007 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 0709512 Country of ref document: GB Kind code of ref document: A Free format text: PCT FILING DATE = 20051109 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 0709512.8 Country of ref document: GB |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11719875 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580042415.4 Country of ref document: CN |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05807910 Country of ref document: EP Kind code of ref document: A1 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 5807910 Country of ref document: EP |